C

큐리옥스바이오시스템즈

445680KOSDAQ의료용 기기 제조업

42.5 / 100

Reference Date: 2026-04-13

Financial Score14.0 / 40
News Sentiment12.5 / 25
Momentum6.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 19.9% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Curiox Biosystems sells automated equipment and consumables for cell analysis processes, leveraging its decade-long developed Curiox C-FREE™ technology to automate preprocessing steps, significantly improving data accuracy and reproducibility. This technology, based on microfluidics and surface science, is used by pharmaceutical companies and research institutions in the US, Europe, and China. The company has subsidiaries in the US, China, and Singapore to expand its global market presence.

Number of Employees

22people

Average Salary

70.4M KRW

Score Calculation Basis

Detailed Financial Score

PER
Industry Average 26.524.0Point
PBR
Industry Average 1.703.5Point
ROE
-53.58Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
3.49Industry Average 10.956.5Point

Half of industry avg (excellent)

Trend 2023~20250.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼10.1% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼9.4% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -30.1% (declining, 3yr)

Detailed News Sentiment

1 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position5.0Point

52w mid range (44%)

Current 74,300Won52-week high 139,60052-week low 22,000
1-month return0.0Point

1m -19.85% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

9 totalPositive 0Neutral 9Negative 0
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-10
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-10
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-10
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-10
  • Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-04-01